Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
1992-2-28
|
pubmed:abstractText |
In breast tumor cell lines, c-myc amplification is frequently associated with estrogen unresponsiveness. We, however, succeeded in characterizing an estrogen-responsive cell line VHB1 derived from a duct cell carcinoma, which exhibits c-myc amplification and overexpression. We therefore studied the effects of estrogen and antiestrogen on c-myc expression in this particular cell line. We also investigated these effects on the expression of c-mil and c-myb oncogenes, also expressed but not amplified in VHB1 cells. Short-(1 h) and long-(72 h) term stimulations were performed. Our experiments showed that estradiol (E2 10(-8) M) was still able to stimulate c-myc expression equally either after short or long-term treatment. In the same way, the antiestrogen 4-hydroxytamoxifen equally decreased c-myc expression but the reversal effect of E2 after long-term antiestrogen treatment was more pronounced than after short-term treatment. The effects of E2 and 4-OH Tam on the expression of the not-amplified c-mil and c-myb oncogenes were stronger than those observed on c-myc expression; however, the E2 reversal effect was identical either after short or long-term antiestrogen treatment. Our results may enlighten some aspects of the complex action of some of the early- and late-growth regulated genes in breast cancer.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/4-hydroxytamoxifen,
http://linkedlifedata.com/resource/pubmed/chemical/Estradiol,
http://linkedlifedata.com/resource/pubmed/chemical/Estrogen Antagonists,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-myb,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-raf,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/Tamoxifen
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0250-7005
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
11
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
2175-9
|
pubmed:dateRevised |
2009-11-19
|
pubmed:meshHeading |
pubmed-meshheading:1776859-Blotting, Northern,
pubmed-meshheading:1776859-Blotting, Southern,
pubmed-meshheading:1776859-Breast Neoplasms,
pubmed-meshheading:1776859-Cell Division,
pubmed-meshheading:1776859-Estradiol,
pubmed-meshheading:1776859-Estrogen Antagonists,
pubmed-meshheading:1776859-Gene Amplification,
pubmed-meshheading:1776859-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:1776859-Genes, myc,
pubmed-meshheading:1776859-Humans,
pubmed-meshheading:1776859-Oncogenes,
pubmed-meshheading:1776859-Proto-Oncogene Proteins,
pubmed-meshheading:1776859-Proto-Oncogene Proteins c-myb,
pubmed-meshheading:1776859-Proto-Oncogene Proteins c-raf,
pubmed-meshheading:1776859-RNA, Neoplasm,
pubmed-meshheading:1776859-Tamoxifen,
pubmed-meshheading:1776859-Tumor Cells, Cultured
|
pubmed:articleTitle |
C-myc overexpression, c-mil, c-myb expression in a breast tumor cell line. Effects of estrogen and antiestrogen.
|
pubmed:affiliation |
U 124 INSERM, Lille, France.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|